| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 31, 2002
From the Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston. * To whom correspondence should be addressed. E-mail: cmacrae{at}partners.org.
Background--Drug-induced QT prolongation and torsades de pointes remain significant and often unpredictable clinical problems. Current in vitro preclinical assays are limited by biological simplicity, and in vivo models suffer from expense and low throughput. Methods and Results--During a screen for the effects of 100 small molecules on the heart rate of the zebrafish, Danio rerio, we found that drugs that cause QT prolongation in humans consistently caused bradycardia and AV block in the zebrafish. Of 23 such drugs tested, 18 were positive in this initial screen. Poor absorption explained 4 of 5 false-negative results, as demonstrated by microinjection. Overall, 22 of 23 compounds that cause repolarization abnormalities were positive in this assay. Antisense "knockdown" of the zebrafish KCNH2 ortholog yielded bradycardia in a dose dependent manner confirming the effects of reduction of repolarizing potassium current in this model. Classical drug-drug interactions between erythromycin and cisapride, as well as cimetidine and terfenadine, were also reproduced. Conclusion--This simple high-throughput assay is a promising addition to the repertoire of preclinical tests for drug-induced repolarization abnormalities. The genetic tractability of the zebrafish will allow the exploration of heritable modifiers of such drug effects.
Revised on January 28, 2003
Accepted on February 3, 2003
Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish
David J. Milan MD,
This article has been cited by other articles:
![]() |
D. J. Milan, A. M. Kim, J. R. Winterfield, I. L. Jones, A. Pfeufer, S. Sanna, D. E. Arking, A. H. Amsterdam, K. M. Sabeh, J. D. Mably, et al. Drug-Sensitized Zebrafish Screen Identifies Multiple Genes, Including GINS3, as Regulators of Myocardial Repolarization Circulation, August 18, 2009; 120(7): 553 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Kalin, N. E. Banziger-Tobler, M. Detmar, and A. W. Brandli An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis Blood, July 30, 2009; 114(5): 1110 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Schlueter and R. T. Peterson Systematizing Serendipity for Cardiovascular Drug Discovery Circulation, July 21, 2009; 120(3): 255 - 263. [Full Text] [PDF] |
||||
![]() |
M. Eijgelsheim, A. L.H.J. Aarnoudse, F. Rivadeneira, J. A. Kors, J. C. M. Witteman, A. Hofman, C. M. van Duijn, A. G. Uitterlinden, and B. H.C. Stricker Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration Hum. Mol. Genet., January 15, 2009; 18(2): 347 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kokel and R. T. Peterson Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish Brief Funct Genomic Proteomic, November 1, 2008; 7(6): 483 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Mangoni and J. Nargeot Genesis and Regulation of the Heart Automaticity Physiol Rev, July 1, 2008; 88(3): 919 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Tran, B. Sneed, J. Haider, D. Blavo, A. White, T. Aiyejorun, T. C. Baranowski, A. L. Rubinstein, T. N. Doan, R. Dingledine, et al. Automated, Quantitative Screening Assay for Antiangiogenic Compounds Using Transgenic Zebrafish Cancer Res., December 1, 2007; 67(23): 11386 - 11392. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Strevel, D. J. Ing, and L. L. Siu Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Stehr, T. L. Linbo, J. P. Incardona, and N. L. Scholz The Developmental Neurotoxicity of Fipronil: Notochord Degeneration and Locomotor Defects in Zebrafish Embryos and Larvae Toxicol. Sci., July 1, 2006; 92(1): 270 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Milan, I. L. Jones, P. T. Ellinor, and C. A. MacRae In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H269 - H273. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Milan, A. C. Giokas, F. C. Serluca, R. T. Peterson, and C. A. MacRae Notch1b and neuregulin are required for specification of central cardiac conduction tissue Development, March 15, 2006; 133(6): 1125 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Costache, P. K. Pullela, P. Kasha, H. Tomasiewicz, and D. S. Sem Homology-Modeled Ligand-Binding Domains of Zebrafish Estrogen Receptors {alpha}, {beta}1, and {beta}2: From in Silico to in Vivo Studies of Estrogen Interactions in Danio rerio as a Model System Mol. Endocrinol., December 1, 2005; 19(12): 2979 - 2990. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Milan and C. A. MacRae Animal models for arrhythmias Cardiovasc Res, August 15, 2005; 67(3): 426 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Hill, H. Teraoka, W. Heideman, and R. E. Peterson Zebrafish as a Model Vertebrate for Investigating Chemical Toxicity Toxicol. Sci., July 1, 2005; 86(1): 6 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kopp, T. Schwerte, and B. Pelster Cardiac performance in the zebrafish breakdance mutant J. Exp. Biol., June 1, 2005; 208(11): 2123 - 2134. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |